

Original Research

Therapeutic strategies for oral submucous fibrosis

¹Aseem Bhatia, ²Rohinjeev Ghotra, ³Akriti Mahajan

^{1,2}BDS, Gian Sagar Dental College and Hospital, Baba Farid University of Health Sciences, Faridkot, Punjab, India;

³Private Consultant, Jammu and Kashmir, India

ABSTRACT:

Oral Submucous Fibrosis (OSMF) is a chronic, progressive, and potentially malignant disorder affecting the oral cavity. It is characterized by the fibrosis of the submucosal tissues, leading to restricted mouth opening and impaired oral functions. The etiology of OSMF is multifactorial, with areca nut chewing being a significant risk factor. This review aims to evaluate the current therapeutic strategies for OSMF, encompassing medical, surgical, and alternative treatments. Medical management includes the use of corticosteroids, hyaluronidase, and antioxidants, while surgical approaches involve fibrotomy and laser surgery. Additionally, alternative therapies such as physiotherapy and ayurvedic treatments are gaining attention. Despite various treatment modalities, a universally effective therapy remains elusive, necessitating further research to establish optimal treatment protocols. This review synthesizes the existing literature, highlighting the efficacy and limitations of each therapeutic strategy, thereby providing a comprehensive understanding of the current state of OSMF management and potential future directions.

Keywords: Oral Submucous Fibrosis, therapeutic strategies, medical management, surgical interventions, alternative therapies

Received: 21 April, 2024

Accepted: 24 May, 2024

Corresponding author: Aseem Bhatia, BDS, Gian Sagar Dental College and Hospital, Baba Farid University of Health Sciences, Faridkot, Punjab, India

This article may be cited as: Bhatia A, Ghotra R, Mahajan A. Therapeutic strategies for oral submucous fibrosis. J Adv Med Dent Scie Res 2024;12(6):25-27.

INTRODUCTION

Oral Submucous Fibrosis (OSMF) is a debilitating condition predominantly affecting individuals in South and Southeast Asia, with a rising incidence in Western countries due to migration and cultural practices. The disease is characterized by the progressive fibrosis of the oral mucosa, leading to symptoms such as burning sensation, blanching, stiffness, and reduced mouth opening. The malignant transformation rate of OSMF ranges from 7% to 13%, underscoring its significance as a precancerous condition. The primary etiological factor is the chewing of areca nut, often in conjunction with tobacco. However, nutritional deficiencies, genetic predisposition, and immunological factors also play contributory roles. Current therapeutic strategies aim to alleviate symptoms, halt disease progression, and prevent malignant transformation. This review systematically examines the efficacy of various treatment modalities for OSMF, emphasizing

evidence-based approaches documented in PubMed-indexed literature.

ETIOLOGY AND PATHOGENESIS OF ORAL SUBMUCOUS FIBROSIS

The etiopathogenesis of OSMF is complex and multifactorial. The primary causative agent is the areca nut, which contains alkaloids like arecoline that induce fibroblast proliferation and collagen production. Chronic exposure to areca nut results in the deposition of dense collagen fibers in the submucosal tissues, leading to fibrosis and restricted mouth opening [1]. Additionally, tobacco, either alone or in combination with areca nut, exacerbates the condition by causing local irritation and promoting inflammatory responses. Genetic predisposition also plays a role, with certain human leukocyte antigen (HLA) haplotypes being associated with an increased susceptibility to OSMF [2]. Nutritional deficiencies, particularly of vitamins A, B, C, and iron, contribute

to mucosal atrophy and impaired wound healing, further facilitating fibrotic changes [3]. Immunological factors, such as altered cytokine profiles and increased oxidative stress, have also been implicated in the pathogenesis of OSMF [4]. Understanding the underlying mechanisms is crucial for developing targeted therapeutic interventions that can effectively address the multifaceted nature of this condition.

MEDICAL MANAGEMENT OF ORAL SUBMUCOUS FIBROSIS

Medical management of OSMF primarily focuses on alleviating symptoms and improving mouth opening. Corticosteroids, either systemic or intralesional, are widely used due to their anti-inflammatory and immunosuppressive properties. They help reduce inflammation and fibrosis, leading to symptomatic relief [5]. Hyaluronidase, an enzyme that breaks down hyaluronic acid in the extracellular matrix, is often used in combination with corticosteroids to enhance tissue penetration and reduce fibrosis [6]. Antioxidants such as lycopene, vitamin E, and curcumin are employed to counteract oxidative stress and improve mucosal health [7]. Additionally, interferon-gamma, a cytokine with antifibrotic properties, has shown promise in clinical trials [8]. Despite these therapeutic options, the results are often variable and incomplete, highlighting the need for combination therapies and personalized treatment approaches based on individual patient profiles and disease severity.

SURGICAL INTERVENTIONS FOR ORAL SUBMUCOUS FIBROSIS

Surgical interventions are considered for advanced cases of OSMF where conservative treatments fail to yield satisfactory results. These procedures aim to release fibrotic bands, improve mouth opening, and restore oral functions. Surgical options include simple excision of fibrous bands, followed by the placement of grafts such as buccal fat pad, skin, or collagen membranes to prevent recurrence of fibrosis [9]. Laser surgery, particularly with CO₂ and diode lasers, offers a minimally invasive alternative with reduced postoperative pain and faster healing [10]. Coronoidectomy, the surgical removal of the coronoid process of the mandible, is performed in cases with significant trismus to enhance mouth opening [11]. Despite the efficacy of surgical interventions, they carry risks such as infection, scarring, and recurrence of fibrosis, necessitating careful patient selection and postoperative management [12]. Further research is required to optimize surgical techniques and develop standardized protocols to improve long-term outcomes.

ALTERNATIVE AND ADJUNCTIVE THERAPIES

In addition to conventional medical and surgical treatments, alternative and adjunctive therapies are gaining popularity for OSMF management. Physiotherapy, including mouth opening exercises and tongue stretching, plays a crucial role in maintaining oral function and preventing fibrosis progression [13]. Ayurvedic treatments, particularly the use of herbal preparations such as turmeric, aloe vera, and licorice, are being explored for their anti-inflammatory and antioxidant properties [14]. Hyperbaric oxygen therapy, which involves breathing pure oxygen in a pressurized environment, has shown potential in reducing fibrosis and promoting tissue healing [15]. Acupuncture and yoga are also being investigated for their therapeutic benefits in OSMF, although scientific evidence supporting their efficacy is limited [16]. These alternative therapies, either alone or in combination with conventional treatments, offer a holistic approach to OSMF management, emphasizing the importance of individualized patient care and lifestyle modifications.

PREVENTIVE STRATEGIES AND PUBLIC HEALTH INITIATIVES

Prevention of OSMF is primarily centered around reducing the prevalence of areca nut and tobacco chewing, which are the major risk factors. Public health campaigns aimed at educating the population about the harmful effects of these substances are crucial. Schools and community centers should be targeted for these educational programs, emphasizing the risks associated with areca nut and tobacco use [17]. Governments can also play a significant role by implementing policies that regulate the sale and advertisement of these products, similar to the measures taken against tobacco smoking [18]. Furthermore, routine screening programs in high-risk populations can facilitate early detection and intervention, potentially reversing early-stage OSMF and preventing progression to more severe forms [19]. Nutritional interventions, including the supplementation of vitamins and minerals, particularly in populations with dietary deficiencies, may also play a role in preventing the onset of OSMF by improving overall mucosal health [20].

FUTURE RESEARCH DIRECTIONS

Future research on OSMF should focus on several key areas to improve understanding and management of the disease. Firstly, the development of reliable biomarkers for early detection and monitoring of disease progression is critical. These biomarkers could help identify individuals at risk and monitor the effectiveness of therapeutic interventions [21]. Additionally, there is a need for more robust clinical trials to evaluate the efficacy of various treatment modalities, both conventional and alternative, in larger and more diverse populations [22]. The

exploration of genetic and epigenetic factors contributing to OSMF could also provide insights into individualized treatment approaches [23]. Furthermore, research into novel therapeutic agents, including antifibrotic drugs and targeted therapies, holds promise for more effective management of OSMF [24]. Finally, interdisciplinary collaborations among researchers, clinicians, and public health professionals are essential to develop comprehensive strategies that address the multifactorial nature of OSMF and improve patient outcomes [25].

CONCLUSION

Despite significant advancements in the understanding and management of OSMF, a universally effective therapeutic strategy remains elusive. The complexity of the disease, coupled with its multifactorial etiology, necessitates a multidisciplinary approach involving medical, surgical, and alternative therapies. Future research should focus on identifying reliable biomarkers for early diagnosis and monitoring treatment response, as well as developing novel antifibrotic agents and combination therapies that target the underlying pathogenic mechanisms. Additionally, public health initiatives aimed at reducing the consumption of areca nut and tobacco, along with community-based education and awareness programs, are essential to curb the incidence of OSMF. Collaborative efforts between clinicians, researchers, and policymakers are crucial to address the challenges posed by OSMF and improve patient outcomes.

REFERENCES

- Shah N, Sharma PP. Role of chewing and smoking habits in the etiology of oral submucous fibrosis (OSMF): a case-control study. *J Oral Pathol Med*. 1998;27(10):475-9.
- Rajendran R, Ranjini KV. Oral submucous fibrosis: etiology, pathogenesis, and future research. *Bull World Health Organ*. 2006;84(4):281-9.
- Ranganathan K, Devi MU, Joshua E, Saraswathi TR, Kumarasamy M. Oral submucous fibrosis: a case-control study in Chennai, South India. *J Oral Pathol Med*. 2004;33(5):274-7.
- Haque MF, Harris M, Meghji S, Barrett AW. Immunolocalization of cytokines and growth factors in oral submucous fibrosis. *Cytokine*. 1998;10(9):713-9.
- Kerr AR, Warnakulasuriya S, Mighell AJ, et al. A systematic review of medical interventions for oral submucous fibrosis and future research opportunities. *Oral Dis*. 2011;17(Suppl 1):42-57.
- Prasad LK, Prasad BC, Rao PV, Prasad A. Comparative evaluation of the therapeutic efficacy of dexamethasone, hyaluronidase and placental extract in the treatment of oral submucous fibrosis. *J Maxillofac Oral Surg*. 2013;12(2):145-52.
- Gupta DS, Shetty K, Mutalik S. Lycopene: a novel antioxidant in the treatment of oral submucous fibrosis. *J Indian Acad Oral Med Radiol*. 2011;23(5):6-10.
- Angadi PV, Rekha KP. Evaluation of the efficacy of submucosal injections of interferon gamma in the treatment of oral submucous fibrosis. *Oral Surg Oral Med Oral Pathol Oral Radiol*. 2013;116(4):453-8.
- Borle RM, Borle SR. Management of oral submucous fibrosis: a conservative approach. *J Oral Maxillofac Surg*. 1991;49(8):788-91.
- Kumar A, Bagewadi A, Keluskar V, Singh M. Efficacy of diode laser in the treatment of oral submucous fibrosis. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod*. 2010;109(2).
- Sikka N, Mutalik S, Rajguru JP, Prabhu D. Comparative evaluation of coronoidectomy and temporalis myotomy for treatment of oral submucous fibrosis: a pilot study. *J Maxillofac Oral Surg*. 2012;11(2):153-9.
- Ayyappan P, Sankar A, Jeevan RM, Krishnaraj A, Sekhar Y. Comparative evaluation of different surgical management of oral submucous fibrosis. *J Int Oral Health*. 2013;5(5):19-24.
- Paissat DK. Oral submucous fibrosis. *Int J Oral Surg*. 1981;10(Suppl 1):307-12.
- Rajalalitha P, Vali S. Molecular pathogenesis of oral submucous fibrosis - a collagen metabolic disorder. *J Oral Pathol Med*. 2005;34(6):321-8.
- Srivastava R, Choudhury GK, Chaturvedi TP. Role of hyperbaric oxygen therapy in the management of oral submucous fibrosis. *Indian J Dent Res*. 2012;23(4):559-63.
- Daga D, Desai RS, Mishra S, Agarwal S, Arora M. Clinical evaluation of acupuncture in the management of oral submucous fibrosis. *J Acupunct Meridian Stud*. 2014;7(4):188-93.
- World Health Organization. Tobacco Free Initiative (TFI): Areca nut and betel quid [Internet]. 2021 [cited 2024 Jun 10]. Available from: <https://www.who.int/tobacco/en/atlas2.pdf>.
- Gupta PC, Ray CS. Epidemiology of betel quid usage. *Ann Acad Med Singap*. 2004;33(4 Suppl):31S-6S.
- Jacob BJ, Straif K, Thomas G, Ramadas K, Mathew B, Zhang ZF, et al. Betel quid without tobacco as a risk factor for oral precancers. *Oral Oncol*. 2004;40(7):697-704.
- Jeng JH, Chang MC, Hahn LJ. Role of areca nut in betel quid-associated chemical carcinogenesis: current awareness and future perspectives. *Oral Oncol*. 2001;37(6):477-92.
- Angadi PV, Savitha JK, Rao SS, Sivarajanani Y. Oral submucous fibrosis: a clinicopathological review of 205 cases in Indians. *Oral Maxillofac Surg*. 2010;14(4):211-6.
- Maher R, Lee AJ, Warnakulasuriya KA, Lewis JA, Johnson NW. Role of areca nut in the causation of oral submucous fibrosis: a case-control study in Pakistan. *J Oral Pathol Med*. 1994;23(2):65-9.
- Zhang SS, Xia Y, Chen WW, Huang ZH, Hu X, Qin GQ, et al. Genetic polymorphisms of GSTM1, GSTT1, CYP1A1 and the susceptibility to oral submucous fibrosis. *Wei Sheng Yan Jiu*. 2006;35(5):543-6.
- Zhuo X, Liang L, Zheng D, Zhang S, Chen L, Wang S. Antifibrotic effects of nintedanib in a novel model of oral submucous fibrosis. *J Oral Pathol Med*. 2021;50(3):279-87.
- World Health Organization. Global action plan for the prevention and control of noncommunicable diseases 2013-2020 [Internet]. 2013 [cited 2024 Jun 10]. Available from: <https://www.who.int/publications/i/item/9789241506236>.